Comparison between maximum consumer prices for medicines and prices practiced on the internet in Brazil:
Caroline Miranda Alves de Souza1, Julia Paranhos1, Lia Hasenclever2
1Instituto de Economia, Universidade Federal do Rio de Janeiro. Av. Pasteur 250 Palácio Universitário, Campus da Praia Vermelha, 22290-902. Rio de Janeiro RJ Brasil. carol_miranda91@ hotmail.com.
Abstract:
Since 2003, the Medicine Market Regulation Chamber (CMED, in portuguese) has been responsible for establishing the maximum consumer prices (MCP) for medicines. The aim of this study is to compare prices practiced on the internet with the MCP and identify the average price difference between them in two segments of existing drugs in Brazil, the reference and the generic ones. Drug prices were collected on websites of pharmacies and drugstores and compared with their respective MCP for the year 2019. The analysis included 68 drugs and 268 commercial presentations of generic and reference drugs related to these drugs. A different pattern was observed for the average price difference in relation to the MCP in each market segment, with most generic drugs tending to show the highest differences and the reference drugs the lowest ones. The problem of price distortion in relation to the MCP pointed out by the literature was confirmed mainly in relation to the generic drug market. It was concluded that a periodic review of the MCP would be important, considering retail prices.
More Related Videos
10:42Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
Published on: June 17, 2022
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Bioequivalence of Drugs: Drugs with Multiple Indications
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmaceutical Equivalents
Bioequivalence: Overview
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
